Press Releases

Sancilio & Company, Inc. presents novel research at the 15th Anniversary Scientific Sessions of the National Lipid Association (NLA).

RIVIERA BEACH, Fla. – May 19th, 2017 Sancilio & Company, Inc. (SCI) announced the participation of members of the leadership and scientific team at the Scientific Sessions of the National Lipid Association (NLA) on May 20th, 2017, in Philadelphia, PA, where they will deliver several novel scientific presentations from the company’s current research. The key … Continue reading Sancilio & Company, Inc. presents novel research at the 15th Anniversary Scientific Sessions of the National Lipid Association (NLA).

FAU and Sancilio Team Up on Therapy for Inherited Blindness

Researchers from FAU and Sancilio and Company, Inc. are collaborating to develop a treatment for Retinitis Pigmentosa, an inherited disease that causes severe progressive vision impairment and blindness. RIVIERA BEACH, Fla. – February 17th, 2017 Researchers from Florida Atlantic University are collaborating with scientists from Sancilio and Company, Inc., in Riviera Beach, Fla., to begin … Continue reading FAU and Sancilio Team Up on Therapy for Inherited Blindness

SCI scientists along with renowned leaders in the field of lipids received acceptance for publication of three peer-reviewed manuscripts.

RIVIERA BEACH, Fla. – January 31st, 2017 SCI scientists along with renowned leaders in the field of lipids received acceptance for publication of three peer-reviewed manuscripts. Such manuscripts, to be e-published soon in Clinical Therapeutics (two) and one in Journal Clinical Lipidology, represent a recognition by these prestigious journals to the seminal work that SCI … Continue reading SCI scientists along with renowned leaders in the field of lipids received acceptance for publication of three peer-reviewed manuscripts.

Leandra Mollanazar joins SCI leadership team

RIVIERA BEACH, Fla. – January 26th, 2017 Sancilio & Company, Inc., (SCI) formally announces the addition of Leandra Mollanazar to the SCI leadership team. Ms. Mollanazar joined SCI on December 2016 as Senior Vice President and General Manager.  Ms. Mollanazar has more than twenty-five years in the pharmaceutical and medical device industries in various executive … Continue reading Leandra Mollanazar joins SCI leadership team

SPCI Launched the SCOT (Sickle Cell Omega-3 Treatment) Trial in the United States with an Investigator Meeting Held December 16-17 in Atlanta

RIVIERA BEACH, Fla. – December 19, 2016 BUSINESS WIRE Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced the start of the first of two placebo controlled clinical trials in US pediatric patients affected with Sickle Cell Disease (SCD). Recruitment in the trial is underway and enrollment is expected to be completed by Q2 2017 and will … Continue reading SPCI Launched the SCOT (Sickle Cell Omega-3 Treatment) Trial in the United States with an Investigator Meeting Held December 16-17 in Atlanta

Sancilio & Company, Inc. Presents at the 12th International Society for the Study of Fatty Acids and Lipids (ISSFAL) Congresssancil

RIVIERA BEACH, Fla. BUSINESS WIRE Sancilio & Company, Inc. (SCI) announced the participation of members of the leadership team at the 12th ISSFAL Congress in Stellenbosch, South Africa where several scientific presentations from the company’s current research will be delivered.

Sancilio Announces US PTO Allowance of Patent Claims

RIVIERA BEACH, Fla.- February 24, 2016 -Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced that the U.S. Patent and Trademark Office allowed the claims of United States Patent Application Nos. 14/456,731 and 14/456,750, which relate to SC401, the company’s drug candidate for the treatment of severe hypertriglyceridemia that was created utilizing the company’s ALT™ platform. Read Full Story … Continue reading Sancilio Announces US PTO Allowance of Patent Claims

Sancilio & Company Recognized By Governor Rick Scott As Manufacturer Of The Year

Riviera Beach, FL, May 4, 2015 – Governor Rick Scott highlighted job creation at Lockheed Martin facility and recognized Sancilio & Company (SCI) as one of three Riviera Beach manufacturing companies recently awarded by the South Florida Manufacturing Association  the “Manufacturer of the Year” Award. The event was held to allow media, local and state leaders to learn[..]

Sancilio and Company Wins Manufacturer of the Year Award from the South Florida Manufacturers Association

Riviera Beach, FL,  March 20, 2015 – Sancilio and Company (SCI), a fully integrated biopharmaceutical company won the Manufacturer of the Year Award from the South Florida Manufacturers Association (SFMA) in Category 3. SCI was one of 20 finalists and was recognized for its excellence in: • Leadership • Strategic Planning • Workforce Focus • Process […]

New Sancilio & Company, Inc. Scientific Board

South Florida Pharmaceutical Company Creates Scientific Advisory Board Riviera Beach, Florida based Sancilio & Company Inc. (SCI) is announcing the creation of the Sancilio Scientific Advisory Board (SSAB). The board’s priority is to take the SCI’s philosophy of looking to nature for pharmaceutical advancements, and insuring the company’s research and development actions are based on […]

Sancilio & Company and Ocean Blue® Partners with Walgreens® in Support of Vitamin Angels®

Sancilio & Company and their Ocean Blue® product line to be part of a major effort to help at-risk populations through Walgreens® and Vitamin Angels®. Palm Beach County, Florida — June 10, 2014 — Sancilio & Company is announcing that their Ocean Blue® brand of natural supplements is teaming up with Walgreens® in support of […]

Finalist in the 2014 SFMA Manufacturer of the Year Award

Sancilio & Company, Inc. (SCI) secured the runner-up position as finalist in the prestigious SFMA Manufacturer of the Year Award Palm Beach County, Florida — April 18, 2014 — Biopharmaceutical company Sancilio & Company, Inc. is pleased to announce it is the runner up as a finalist in the SFMA Manufacturer of the Year Award for […]

Sancilio & Company, Inc. Announces Redesign of Their Website

Palm Beach County, Florida — March 12, 2014 — Biopharmaceutical company Sancilio & Company, Incorporated (SCI) proudly announces the redesign of its website, Sancilio.com. The website’s fresh look, inside view into the company’s facility and product information showcase SCI’s pharmaceutical development and manufacturing, while creating a pleasant user experience for consumers and global partners. “The […]

Keiser University Expands Internship Opportunities with Sancilio & Company, Inc.

  February 13, 2014 The partnership between the Port St. Lucie campus of Keiser University and Sancilio & Company, Inc. recently expanded to include internship opportunities for Graphic Art and Design students. For the past year, students from the Biotechnology program have had the opportunity to gain real-world experience from the company through valuable internships […]

Sancilio and Company Announces Life Sciences Consulting Services

Riviera Beach, Florida,  January 10, 2013 – Sancilio and Company, Inc. (SCI), a vertically integrated pharmaceutical company located in Palm Beach County, Florida, is pleased to announce its offering of a full suite of life sciences consulting services.  Led by a team of experts with broad experience and insight, SCI now offers consulting support for […]

December 24th, 2013: Sancilio & Company is named a Class of 2013 Florida Companies to Watch Award winner

December 24th, 2013 – The maker of Ocean Blue® omega-3 fatty acid supplements is recognized for distinguished leadership, innovation and impact Florida-based Sancilio & Company has earned a prestigious 2013 Florida Companies to Watch Award in recognition of its distinguished leadership, innovation and impact. Criteria for this award, presented by GrowFL, included demonstrated high performance […]

December 24th, 2013: Sancilio and Company (SCI) successfully concludes the terms of its Town of Jupiter Economic Development Loan

December 20th, 2013 – Jupiter’s Economic Development Loan Program promotes the growth of pharmaceutical and biotechnology companies in northern Palm Beach County. The Town of Jupiter, Florida and Sancilio and Company (SCI), a Palm Beach County-based pharmaceutical company, are pleased to announce full repayment of SCI’s economic development loan. The loan was guaranteed by the Town of Jupiter […]

December 9, 2013: Sancilio and Company, Inc. Files IND Application with U.S. FDA for SC401

Riviera Beach, FL – December 9, 2013 – Sancilio and Company, Inc. (SCI) today announced its submission of an investigational new drug (IND) application to the U.S. Food & Drug Administration (FDA) for a pivotal Phase 3 study of its lead investigational drug, SC401™. SC401 is a combination of highly refined eicosapentaenoic acid (EPA) and […]

December 2, 2013: BDB Announces New Jobs Coming to Palm Beach County

West Palm Beach, Fla. – December 2, 2013 – The Business Development Board of Palm Beach County announced that it has assisted two local businesses expand their operations in Palm Beach County and recruited two new companies to the area resulting in 80 new and 153 retained jobs. Expansion/Retention Projects: In cooperation with the City […]

September 10, 2013: Sancilio & Company is Named a Class of 2013 Florida Companies to Watch Award Winner

Riviera Beach, FL (PRWEB) September 10, 2013 – The maker of Ocean Blue® omega-3 fatty acid supplements is recognized for distinguished leadership, innovation and impact. Florida-based Sancilio & Company has earned a prestigious 2013 Florida Companies to Watch Award in recognition of its distinguished leadership, innovation and impact. Criteria for this award, presented by GrowFL, […]

August 06, 2013: Ocean Blue® Omega-3 Products in CVS Stores Located Throughout the Nation

Riviera Beach, Florida – August 06, 2013 – Consumers can now purchase the entire line of Ocean Blue® Omega-3 MiniCaps® products in CVS stores located throughout the nation. Sancilio & Company, Inc. announces that Ocean Blue® Omega-3 and Omega-3 + Vitamin D3 MiniCaps® are now available at CVS stores across the country. Healthy consumers can […]

June 11, 2013: Sancilio & Company Introduces a New Omega-3 Unit Dose Packaging

Riviera Beach, FL (PRWEB) June 11, 2013 – Sancilio and Company, Inc. (SCI), a leader in Advanced Lipid Technology and improvements of Omega-3 essential fatty acids announces the availability of Unit Dose Omega-3 packaging. Sancilio and Company, Inc. (SCI), a leader in Advanced Lipid Technology and improvements of Omega-3 essential fatty acids, announces the availability […]

May 15, 2013: Sancilio and Company Announces the Redesign Launch of its Omega-3 Product Line Ocean Blue© Professional Omega-3 2100™

Riviera Beach, Florida – May 15, 2013 – Sancilio and Company, a leader in Advanced Lipid Technology improvements of omega-3 essential fatty acids, proudly announces the release of their newly redesigned Ocean Blue© Professional Omega-3 2100™ product line. The newly designed product line boasts a vibrant yellow color pallet and modern logo. In addition, SCI […]

July 23, 2012: Sancilio and Company Announces New Directors

RIVIERA BEACH, Fla., July 23, 2012 — Sancilio and Company, Inc. (SCI) is pleased to announce the recent addition of Dr. Alan Dunton, Mr. Patrick Gray, Mr. Rod Jackson, Dr. Dennis Langer and Mr. Kelly Perkins to its Board of Directors. The new directors join the Company’s Chairman, Dr. Frederick Sancilio, who is also Founder, President […]

April 11, 2010: Made in Palm Beach County: Riviera Beach drugmaker takes on overseas competitors

RIVIERA BEACH — April 11, 2010 By Jeff Ostrowski As drug manufacturers flee the United States for India and China, entrepreneur Fred Sancilio hopes to prove that America remains a profitable place to make pills. His firm, Riviera Beach-based Sancilio & Co., churns out a variety of drugs and supplements, including prescription medicines for other […]

Development and Validation of a Single HPLC Method for Analysis of Purines in Fish Oil Supplements

Gout is one of the most common forms of inflammatory arthritis, affecting over 8 million adults in the US. Individuals with gout are advised to avoid the habitual intake of purine-rich foods such as meats, seafood, purine-rich vegetables, and animal protein. An increased risk of developing or having subsequent attacks of gout is particularly associated […]

Quantitative FTIR Analysis of Paraben in Finished Dosage Pharmaceuticals

Parabens are the most widely used preservatives in the pharmaceutical industry due to their broad antimicrobial properties, relatively low toxicity, low volatility, and high stability. Parabens are esters of p-hydroxybenzoic acid, which are active against yeast, fungi, molds, and Gram-positive bacteria (1). Activity increases with increased alkyl chain length (butyl> propyl> ethyl> methyl) and parabens […]

Sancilio – Genesis Study

A dietary supplement with a high Eicosapentaenoic Acid to Docosahexaenoic Acid ratio reduces Triglycerirde Levels in Mildly Hypertriglyceridemic subjects. Download the PDF file here: Sancilio – Genesis Study

Busting the Most Common Fish Oil Myths

If you take a fish oil supplement to help lower your LDL cholesterol, you’re wasting your money. The same may hold true if you think there’s not much difference between the various types of fish oil and omega-3 supplements on store shelves except perhaps the capsule sizes (and the size of the smelly, fishy belches […]

A Dietary Supplement with a High Eicosapentaenoic Acid to Docosahexaenoic Acid Ratio Reduces Triglyceride Levels in Mildly Hypertriglyceridemic Subjects

A Dietary Supplement with a High Eicosapentaenoic Acid to Docosahexaenoic Acid Ratio Reduces Triglyceride Levels in Mildly Hypertriglyceridemic Subjects. Download the PDF file here: A Dietary Supplement with a High Eicosapentaenoic Acid to Docosahexaenoic Acid Ratio Reduces Triglyceride Levels in Mildly Hypertriglyceridemic Subjects

Prevention Of Cardiovascular Disease with Omega-3 Polyunsaturated Fatty Acids

Large scale-epidemiological studies and recent clinical studies have demonstrated that individuals at risk for coronary heart disease (CHD) benefit from consuming omega-3 long-chain polyunsaturated fatty acids (n-3FA). Download the PDF file here: Prevention Of Cardiovascular Disease with Omega-3 Polyunsaturated Fatty Acids (PDF)

Effect of omega-3 (n−3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial1,2,3

Ahmed A Daak,  Kebreab Ghebremeskel, Zahir Hassan, Bakhita Attallah,  Haj H Azan, Mustafa I Elbashir, and Michael Crawford Abstract Background: Blood cell aggregation and adherence to vascular endothelium and inflammation play a central role in vaso-occlusive crisis in sickle cell disease. The antiaggregatory, antiadhesive, antiinflammatory, and vasodilatory omega-3 (n−3) fatty acids (DHA and EPA) are significantly reduced in patients … Continue reading Effect of omega-3 (n−3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial1,2,3

A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid TechnologiesTM (ALT®) Improves Docosahexaenoic Acid and Eicosapentaenoic Acid Bioavailability Compared with Lovaza®

Miguel A. Lopez-Toledano, Thorsteinn Thorsteinsson,  Ahmed Daak, Kevin C. Maki, Colleen Johns,  Adrian L. Rabinowicz, and Frederick D. Sancilio Abstract Purpose: The US Food and Drug Administration has approved several highly purified ω-3 fatty acid prescription drugs for the treatment of severe hypertriglyceridemia. These differ in the amounts and forms of docosahexaenoic acid (DHA) and/or … Continue reading A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid TechnologiesTM (ALT®) Improves Docosahexaenoic Acid and Eicosapentaenoic Acid Bioavailability Compared with Lovaza®

Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance

Kevin C. Maki, Colleen Johns,  William S. Harris,  Mark Puder,  Steven D. Freedman, Thorsteinn Thorsteinsson, Ahmed Daak, Adrian L. Rabinowicz, and Frederick D. Sancilio Abstract The US Food and Drug Administration (FDA) draft guidance for establishing bioequivalence (BE) of ω-3 acid ethyl esters (containing both eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] as ethyl esters), used … Continue reading Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance

Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3 acid ethyl esters with an Advanced Lipid TechnologiesTM (ALT®)-based formulation

M.A. Lopez-Toledano, T. Thorsteinsson, A.A. Daak, K.C. Maki, C. Johns, A.L. Rabinowicz, and Fred Sancilio Highlights SC401, is a new formulation of omega-3 fatty acids with enhanced bioavailability. SC401 has Advanced Lipid TechnologiesTM (ALT®) that forms stable micelles. SC401 reduces the food effect on DHA and EPA bioavailability. SC401 could be a good treatment for … Continue reading Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3 acid ethyl esters with an Advanced Lipid TechnologiesTM (ALT®)-based formulation

Use of a novel docosahexaenoic acid formulation vs control in a neonatal porcine model of short bowel syndrome leads to greater intestinal absorption and higher systemic levels of DHA

Camilia R. Martin, Barbara Stoll, Joanne Cluette-Brown, Adesola C. Akinkuotue, Oluyinka O. Olutoye, Kathleen M. Guraf, Pratibha Singhd, Munir M. Zamand, Michael C. Perillo, Mark Puderg, Steven D. Freedman, Doug Burrin Abstract Infants with short bowel syndrome (SBS) are at high risk for malabsorption, malnutrition, and failure to thrive. The objective of this study was … Continue reading Use of a novel docosahexaenoic acid formulation vs control in a neonatal porcine model of short bowel syndrome leads to greater intestinal absorption and higher systemic levels of DHA

fpo

Google+   Likedin